Drug Approval | March 28, 2022
EU approves Evusheld to prevent Covid-19
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Vela Analytics can create concise, evidence-based in-house reports that help customers with the information to make timely, informed decisions about possible treatment options
Registration is open for the global event that invites technology enthusiasts to bring innovative ideas to improve healthcare outcomes
The company’s differentiated value proposition comes during a time of unprecedented disruption in the life science supply chain
It also empowers domestic precision immunotherapy for tumours and promotes the high-quality development of China's biopharmaceutical industry
The implementation of ScienceMedia's solutions will ultimately help AMCR collapse patient recruitment and enrollment
More than 120 speakers and 5,000 delegates are expected to attend
Arizona-based, leading medical devices company, Confluent Medical Technologies, will be establishing a pilot manufacturing facility in Hyderabad.
The enhanced portfolio includes the Scenaria View, Supria series, The Echelon Smart and Arietta series
Aquavit will officially unveil the Dermatox and Microtox programs at the Annual American Academy of Dermatology, the world's largest dermatology conference scheduled from March 25-29, 2022, in Boston, MA
Subscribe To Our Newsletter & Stay Updated
